İsrail - İngilizce - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - sugammadex - solution for injection - sugammadex 100 mg/ml - sugammadex - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; ascorbyl palmitate; potato starch; lactose monohydrate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, xyvion should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). xyvion should only be continued for as long as the benefit outweighs the risks.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; potato starch; lactose monohydrate; ascorbyl palmitate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, livial should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). livial should only be continued for as long as the benefit outweighs the risks.

İsrail - İngilizce - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - sugammadex - solution for injection - sugammadex 100 mg/ml - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium.

İsrail - İngilizce - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rocuronium bromide - solution for injection - rocuronium bromide 10 mg/ml - rocuronium bromide - rocuronium bromide - adjunct to general anaesthesia to facilitate tracheal intubation, to provide skeletal muscle relaxation during surgery. esmeron indicated as an adjunct in the intensive care unit (icu) to facilitate tracheal intubation and mechanical ventilation.

Singapur - İngilizce - HSA (Health Sciences Authority)

organon singapore pte. ltd. - desloratadine - tablet, film coated - 5 mg - desloratadine 5 mg

Singapur - İngilizce - HSA (Health Sciences Authority)

organon singapore pte. ltd. - mometasone furoate monohydrate eqv mometasone furoate - spray - 50 mcg/dose - mometasone furoate monohydrate eqv mometasone furoate 50 mcg/dose

Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - betamethasone dipropionate -

Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - simvastatin -

Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - simvastatin -